📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
2 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BULLISH
TOTAL VIEWS
4
RECENT COVERAGE · 3 ARTICLES
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
SNDX faces revised market expectations for its acute myeloid leukemia (AML) pipeline, with analyst Brad Canino at Guggenheim trimming...
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX)
Syndax Pharmaceuticals (SNDX) has transitioned into a validated multi-product oncology platform, with both Revuforj and Niktimvo...
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Pharmaceuticals (SNDX) presented clinical data for revumenib (Revuforj®) at the European Hematology Association 2026 conference,...
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice